Intrathecal Prophylaxis Should NOT Be Given to PMBCL Patients Receiving R-DAEPOCH
Routine intrathecal (IT) CNS prophylaxis is not recommended for primary mediastinal B-cell lymphoma (PMBCL) patients treated with R-DAEPOCH, as the CNS relapse rate is exceedingly low (approximately 1-2%) and IT prophylaxis has not been shown to prevent the predominantly parenchymal relapses that occur in this population.
Why PMBCL is Different from Other DLBCL Subtypes
PMBCL is a distinct entity that shares biological features with nodular sclerosis Hodgkin lymphoma, which has minimal CNS relapse risk. The most recent data from 2025 demonstrates that among 154 PMBCL patients treated with standard chemoimmunotherapy, the cumulative incidence of CNS relapse was only 2.21% at 5 years 1. Critically, all three CNS relapses occurred with concurrent systemic disease, and IT prophylaxis failed to prevent relapse in the one patient who received it 1.
The Evidence Against IT Prophylaxis in PMBCL
CNS Relapse Patterns Make IT Prophylaxis Ineffective
Parenchymal predominance: When CNS relapses occur in DLBCL (the broader category), 58% are parenchymal, 27% leptomeningeal, and 12% both 2. IT chemotherapy only addresses leptomeningeal disease and cannot prevent brain parenchymal involvement.
IT prophylaxis doesn't work even in high-risk DLBCL: A 2020 systematic review of 7,357 rituximab-exposed DLBCL patients found that IT prophylaxis was not associated with reduced CNS relapse in univariable or multivariable analysis in any study examined 2. A 2015 study of 322 DLBCL patients showed no significant difference in CNS relapse between those receiving IT-MTX prophylaxis (8%) versus those who did not (3%) 3.
PMBCL Has Inherently Low CNS Risk
The 2025 Mayo Clinic analysis specifically examined PMBCL patients and found that among 131 patients who did NOT receive CNS prophylaxis, the CNS relapse rate was only 1.80% at both 2 and 5 years 1. This is far below the threshold that would justify routine prophylaxis.
What the Guidelines Actually Say
The available guidelines address DLBCL broadly but do not specifically recommend CNS prophylaxis for PMBCL:
Spanish Lymphoma Group (GELTAMO) 2017: Recommends CNS prophylaxis for high-risk DLBCL patients, specifically mentioning testicular, renal, or adrenal involvement 4. PMBCL is notably absent from high-risk categories.
ESMO 2015: Recommends CNS prophylaxis for patients with high-intermediate or high-risk IPI, multiple extranodal sites, elevated LDH, or testicular/renal/adrenal involvement 5. Again, PMBCL is not specifically identified as requiring prophylaxis.
These guidelines were written for DLBCL in general and predate the specific PMBCL data showing extremely low CNS relapse rates.
R-DAEPOCH Specific Considerations
The landmark 2013 study of DA-EPOCH-R in 51 PMBCL patients achieved 93% event-free survival and 97% overall survival without routine CNS prophylaxis 6. No CNS relapses were reported in this cohort, further supporting that this intensive regimen does not require additional CNS-directed therapy.
Common Pitfalls to Avoid
Don't extrapolate from general DLBCL data: PMBCL is biologically distinct and has different relapse patterns than other DLBCL subtypes.
Don't assume IT prophylaxis prevents parenchymal disease: The majority of CNS relapses in aggressive lymphomas are parenchymal or combined, which IT chemotherapy cannot prevent.
Don't add unnecessary toxicity: IT chemotherapy carries risks of headache, nausea, infection, and rarely, neurotoxicity, without proven benefit in this population.
When to Consider CNS-Directed Therapy
CNS prophylaxis might be considered only in the exceptional PMBCL patient who has:
- Concurrent high-risk extranodal sites (testicular, renal, adrenal involvement)
- Documented CNS involvement at diagnosis (which would require treatment, not prophylaxis)
For standard PMBCL patients receiving R-DAEPOCH, omit routine IT prophylaxis and focus on delivering optimal systemic therapy 6, 1.